FDA doubles down on overall survival
New draft guidance could see the agency getting ever stricter.
New draft guidance could see the agency getting ever stricter.
Jazz’s Chimerix buy faces its big test.
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
Tough equity markets as well as competitor developments prompt a narrowed focus.